TP53 PVs are identified in approximately 30% patients fulfilling Chompret criteria and up to 75% of patients with classic LFS.3 This discussion focused on whether we would offer surveillance only to patients with confirmed PVs in TP53, those who meet clinical criteria for LFS but do not have a confirmed TP53 PV or those with PVs predicted to be of lower penetrance for example, the Brazilian founder PV c.1010G>A, p.ArgR337His. This evidence concerns the gene TP53 and perivascular space measurement.